撰文丨王聪 编辑丨王多鱼 排版丨水成文 衰老 是一个复杂的过程，涉及全身各系统细胞和分子层面的多种变化，导致功能逐渐衰退。寻找有效策略来对抗与衰老相关的变化是一项重要的科学探索，具有 深远的社会意义，因为这有可能改善整体健康状况并延长健康寿命。许多策略已显示出有希望的实验数据，例如 mTOR 抑制剂、衰老细胞清除药物、NAD 增强 剂、牛磺酸补充剂、间歇性禁食和热量限制、细胞重编程等。对这些方法的研究极大地推进了我们对衰老过程的理解，并增强了我们对抗衰老的能力。 理想的抗衰老方法应具备以下若干特点，包括：1）采用药物手段以利于实际应用；2）具有良好的安全性，治疗窗口宽，易于实现良好的效益与副作用平衡；3） 对影响衰老过程中不同器官系统的各种疾病具有广泛的潜在适用性；4）在年龄相关疾病的其他治疗靶点之间存在潜在机制协同作用，从而能够实现联合治疗。 尽管上述方法前景广阔，但每种方法都有其自身的挑战和局限性。迄今为止，许多方法仍需在一项或多项关键属性方面进一步完善和发展，才能应用于临床。 2025 年 11 月 19 日，香港中文大学 高浩 、 莫仲棠 、 黄俊哲 等人在 Cell 子刊 Cell Metaboli ...

Core Viewpoint - The emergence of a new era in disease prevention is highlighted, with GLP-1 receptor agonists (GLP-1s) potentially becoming the first longevity drugs due to their efficacy in treating obesity and type 2 diabetes, as well as their benefits in mitigating age-related chronic diseases [3][4][12]. Group 1: GLP-1s and Longevity - GLP-1s show promise not only in treating obesity and diabetes but also in preventing various age-related diseases, marking a shift towards preventive medicine [4][12]. - Clinical trial data indicates that GLP-1s significantly improve cardiovascular outcomes and reduce all-cause mortality in high-risk populations, with some benefits attributed to anti-inflammatory mechanisms rather than weight loss alone [12][13]. Group 2: Aging Mechanisms and Drug Development - Aging is identified as a major risk factor for late-life diseases, and targeting aging mechanisms could theoretically prevent multiple diseases simultaneously [6][9]. - Research has categorized aging markers into 14 distinct categories, which include genetic, epigenetic, and cellular factors, forming a complex network that is challenging to measure [6][9]. Group 3: Current Status and Future Directions - No anti-aging drugs have been approved yet, although some existing medications may meet the criteria if properly tested. The FDA does not recognize aging as a disease, complicating the regulatory landscape for anti-aging interventions [10][12]. - Ongoing trials are exploring the effects of GLP-1s on diseases beyond obesity and diabetes, including Alzheimer's disease, with promising early results [13][14]. Group 4: Challenges and Considerations - The exploration of GLP-1s for longevity will involve various factors such as disease indicators, formulations, and individual patient responses, with a focus on minimizing side effects [14][16]. - The success of longevity drugs will likely depend on their long-term safety, efficacy, affordability, and the ability to be used in precision medicine approaches [14][16]. Group 5: Broader Research and Development - Pharmaceutical companies are investigating various strategies beyond GLP-1s, including targeting inflammation and other pathways associated with aging, which may have broad implications for healthspan [16][17]. - The TAME trial proposes a more efficient method of assessing multiple chronic diseases as composite outcomes, which could facilitate the approval of anti-aging drugs [17].

Summary of the Conference Call for Furuida Company Overview - **Company**: Furuida - **Year**: 2025 - **Industry**: Cosmetics, Pharmaceuticals, and Raw Materials Key Points Overall Performance Expectations - Furuida's overall performance in 2025 is expected to be flat, with a slight decline in cosmetics business, stable growth in raw materials, and pressure in the pharmaceutical sector [2][29][30] Brand Performance - **Yilian Brand**: Despite a decline during the Double Eleven sales event, the annual growth expectation remains at 15%-20%, with the cooking series products performing well and improving overall gross margin [2][5] - **Doctor Brand**: The probiotic series adjustment is nearing completion, with some face masks resuming shipment. Positive growth is anticipated for next year [2][11] - **Kemi Brand**: Expected to achieve triple-digit growth, with sales projected to reach around 100 million due to the success of the Chuangmo peptide technology and collaboration with Xinhua Net [2][21] Raw Materials Business - Significant growth in the raw materials business in Q3, driven by high demand for food-grade and cosmetic-grade hyaluronic acid, as well as rapid expansion in the overseas market for pharmaceutical-grade hyaluronic acid [2][25][27] Sales Channels - Douyin has become the largest sales channel, accounting for approximately 60% of online sales, while Tmall accounts for about 40% [8][6] - The self-broadcasting and other channels have maintained rapid growth despite the absence of top-tier influencer collaborations [6][8] Product Structure and Innovations - The proportion of spray products in the Yilian brand has risen to over 70% due to successful sales of the spray kit endorsed by Zhang Linghe [9] - The 287 series is positioned to replace the original probiotic series, focusing on specific skin issues and improving product quality [16] Future Plans and Strategies - Plans to advance equity incentives and acquisition strategies in 2026, with preparations already underway [12][34] - The company is exploring new directions in the pharmaceutical sector, including online pharmacies and health food products, although these require time and investment for scaling [28] Market Outlook - The company remains optimistic about 2026, expecting positive effects from current adjustments and a favorable market environment [29][33] - The pharmaceutical business is under pressure, but the company is actively seeking new growth avenues [28] Financial Performance - The company aims to improve profitability through enhanced gross margins and various measures despite a flat overall performance in 2025 [30] Regulatory and Certification Updates - Anticipation of receiving three types of certifications for pharmaceutical-grade hyaluronic acid by late 2026 or early 2027, which could significantly boost sales [23][24] Competitive Landscape - The competition between Tmall and Douyin is seen as beneficial, providing more promotional opportunities for the company [19] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Furuida's current performance, brand dynamics, market strategies, and future outlook.

Core Insights - The research team from Tongji University discovered that the naked mole rat possesses a unique protein, cGAS, which functions oppositely to its human counterpart, aiding in DNA repair and contributing to the animal's longevity [1][2] - The study highlights the significance of DNA repair capabilities in determining species lifespan, with naked mole rats living up to 40 years and showing resistance to various diseases [1] - The findings were published in the international journal "Science," providing new targets for anti-aging interventions [1] Group 1 - The naked mole rat's cGAS protein enhances homologous recombination repair efficiency, contrasting with the human cGAS protein that inhibits this process [1][2] - The research identified four evolutionarily specific amino acid sites in the C-terminal domain of naked mole rat cGAS that mediate the reversal of function [2] - Mutating these sites in naked mole rat cGAS leads to the loss of its DNA repair-promoting function, while introducing them into human cGAS can reverse its aging-promoting effects [2] Group 2 - Overexpression of naked mole rat cGAS in mice helps resist multi-organ aging, reduces systemic inflammation, and extends healthy lifespan [2] - The study explores the unique DNA repair mechanisms of naked mole rats and their association with longevity, potentially offering new insights for achieving "aging without decline" in humans [2]

Core Viewpoints - Semaglutide is recognized as a significant medical breakthrough with potential applications beyond obesity and sleep apnea, including treatment for various diseases such as heart failure, arthritis, Alzheimer's, and cancer [2][4]. - The drug's ability to improve cardiovascular metabolic health suggests far-reaching benefits that could revolutionize cardiovascular care [2][4]. Group 1: Medical Applications - Semaglutide shows potential in treating multiple diseases, including heart failure, arthritis, Alzheimer's, and cancer, by improving overall health and potentially delaying aging [4]. - The Select trial involved over 17,600 patients aged 45 and above with obesity or overweight and cardiovascular disease risk, demonstrating a significantly lower all-cause mortality rate in the semaglutide group compared to the placebo group [4]. Group 2: Efficacy and Safety - In patients taking semaglutide, the mortality rate from COVID-19 was 2.6%, compared to 3.1% in the placebo group, indicating a significant reduction in death rates despite similar infection risks [6]. - Semaglutide effectively reduces the risk of severe cardiovascular events and alleviates heart failure symptoms, regardless of weight loss [6]. Group 3: Drug Mechanism and Usage - Semaglutide, marketed under the brand names Wegovy and Ozempic, mimics the GLP-1 hormone to induce satiety and reduce hunger, administered via injection [6]. - Experts caution that semaglutide is not a panacea and should not replace healthy diet and exercise, emphasizing the importance of medical supervision to avoid potential side effects [6]. Group 4: Future Research and Implications - Ongoing research is exploring the potential of semaglutide and similar drugs in combating age-related diseases, indicating a promising future for longevity biotechnology in global health systems [6]. - The era of semaglutide in medicine is just beginning, with its comprehensive impact still requiring further study and observation [6].

Core Insights - The high-priced traditional Chinese medicine (TCM) products, such as An Gong Niu Huang Wan and Pian Zai Huang, are experiencing a decline in both sales and prices, prompting investors to reconsider the consumption logic of these products [2][3][4]. Group 1: Sales and Price Trends - An Gong Niu Huang Wan and Pian Zai Huang have seen a significant drop in sales and prices, with Pian Zai Huang's revenue decreasing by 11.93% and net profit down by 20.74% in the first three quarters of the year [4]. - The retail price of Pian Zai Huang has fallen below the official guidance price of 760.00 yuan per piece, with online platforms offering prices as low as 588.60 yuan [4][5]. - An Gong Niu Huang Wan is also facing price declines, with sales figures indicating a broader trend affecting high-priced TCM products [5]. Group 2: Market Dynamics - The decline in high-priced TCM sales is attributed to a fundamental change in consumer behavior, shifting from luxury and gift-giving to a focus on genuine patient needs [5][10]. - Tightening medical insurance policies have also impacted sales, as certain high-priced products are not fully covered, affecting consumer purchasing decisions [5][10]. - Despite the decline in high-priced TCM, there is a growing demand for anti-aging and health supplement products, which are becoming key drivers of growth in the health market [9][10]. Group 3: Growth in Alternative Products - Products like Gui Ling Ji and Ba Zi Bu Shen capsules are witnessing steady price and sales increases, indicating a shift in consumer preference towards health and wellness products [1][10]. - The market for health supplements, particularly those targeting the aging population, is expanding, with significant growth reported in products like Ejiao, which saw a 16.48% increase in sales in 2024 [11][14]. - The aging population in China is projected to reach 310.31 million by the end of 2024, representing 22.0% of the total population, further driving demand for health-related products [10].

Core Viewpoint - The "2025 International Genomics Conference on Ophthalmology (ICG EYE) and CGT Innovation and Industrial Transformation Summit" highlighted the integration of cell and gene therapy (CGT) in eye health and anti-aging applications, showcasing new ideas, trends, technologies, and results [1] Group 1: Event Overview - The conference featured a forum themed "CGT + Anti-Aging Mechanisms and Applications," where experts and industry leaders engaged in discussions on practical applications of CGT in eye health and anti-aging [1] - The event served as a platform for international exchange, fostering innovation in the integration of CGT technology with eye health and anti-aging fields [1] Group 2: Company Initiatives - Liaoning He’s Eye Hospital Group Co., Ltd. (301103) collaborated with various institutions to form a synergistic innovation matrix, focusing on precision medicine [1] - The company established the first eye gene bank and clinical application research center for ophthalmic stem cells in China, targeting eye health, anti-aging, and longevity technology [1] Group 3: Research Focus - The company is concentrating on three core areas: gene therapy, stem cell regenerative medicine, and intelligent ophthalmic equipment data applications [1] - The aim is to conduct cutting-edge technology research to address complex eye disease issues and promote the deep integration of technology with healthcare data [1] Group 4: Market Expansion - The company is actively expanding into overseas markets to promote the globalization and accessibility of regenerative medical technologies [1] - The successful forum is expected to inject innovative momentum into the high-quality development of eye health and longevity industries as related technologies accelerate and the ecosystem improves [1]

Core Insights - The article highlights the rising popularity of ergothioneine, particularly in the context of the upcoming Double Eleven shopping festival, with significant sales figures reported for brands promoting anti-aging products [1][2]. Group 1: Scientific Research and Development - Research on ergothioneine has primarily focused on its efficacy, with significant contributions from Chinese scientists, particularly a breakthrough study published in *Nature* in 2015 that revealed its role in antibiotic synthesis [2][6]. - The discovery of specific transport proteins for ergothioneine has established it as a key molecule related to human health, beyond its antioxidant properties [6][7]. Group 2: Market Growth and Projections - The global market for ergothioneine is projected to grow from approximately $39.59 million in 2023 to $806 million by 2033, reflecting a compound annual growth rate (CAGR) of 36.2% [8]. - The increasing demand for antioxidant and anti-aging ingredients is driving this market growth, alongside advancements in production technology [8]. Group 3: Production Methods - Three main methods for synthesizing ergothioneine have been identified: chemical synthesis, chemical synthesis combined with enzymatic catalysis, and precision fermentation [10][12][13]. - Precision fermentation is viewed as the most promising method for sustainable and cost-effective production, leveraging microorganisms with ergothioneine biosynthesis capabilities [14][15]. Group 4: Applications in Health and Food Industry - Ergothioneine is being explored for use in dietary supplements and health products, with companies like Tetrahedron and Blue California leading the way in industrial applications [18][19]. - Its potential as a natural preservative and antioxidant in food products is also being recognized, with applications in seafood preservation and functional foods [21][23]. Group 5: Regulatory Approvals and Market Entry - Ergothioneine has received regulatory approvals in the EU and the US, allowing its use in various food products and dietary supplements, which has facilitated its market entry [24][25]. - The article notes that while ergothioneine has gained recognition in international markets, its approval process in China is still ongoing, with several applications pending [27][28].

Core Viewpoint - The company has entered into a joint venture agreement with NAGAWA Pharmaceutical Co., Ltd and Mirxes Pte Ltd to establish a new company in Hong Kong, focusing on anti-aging products and solutions [1] Group 1: Joint Venture Details - The joint venture will have a registered capital of HKD 50 million, with the company holding 75% ownership, NAGAWA Pharmaceutical 20%, and Mirxes Pte Ltd 5% [1] - The new company aims to invest in and operate research and sales of anti-aging products in Hong Kong and selected Asia-Pacific countries [1] Group 2: Strategic Objectives - This collaboration addresses the changing consumer demands for "healthy lifespan" and "beauty lifespan," enhancing customer lifetime value and loyalty [1] - The initiative marks a shift from providing external beauty services to offering comprehensive beauty and health solutions [1] - The venture is expected to create significant cross-selling opportunities, improve the company's brand image, establish a competitive advantage in the medical anti-aging sector, and ultimately generate sustainable revenue streams for long-term shareholder value [1]

Investment Rating - The report maintains a "Positive" investment rating for the industry [8] Core Insights - NAD+ is a crucial coenzyme involved in fundamental life processes, with its levels declining during aging, leading to increased interest in NAD+ supplements like NMN and NR for anti-aging solutions [2][4][5] - The NAD+ market is driven by the growing demand for anti-aging products, with significant players like Swisse, H&H International, and Goldenway actively participating in the sector [7][27] - Regulatory environments vary across regions, with the U.S. showing signs of loosening regulations, while China maintains strict approval processes for NAD+ related supplements [6][26] Summary by Sections NAD+ as an Important Coenzyme - NAD+ is present in all active cells and plays a role in metabolism, energy synthesis, and DNA repair [4][17] - The decline of NAD+ levels is linked to aging, making its supplementation a key focus in the health product industry [5][20] Regulatory Environment - In the U.S., there are indications of potential regulatory easing for NAD+ supplements, particularly NMN, while NR remains stable in the market [6][26] - The EU is cautiously opening up, with NR approved as a "novel food" and NMN undergoing safety assessments [6][26] - China has the strictest regulations, with no local production allowed for NMN and NR due to ongoing debates regarding their clinical efficacy [6][26] Market Players and Product Development - Key companies like Goldenway are expected to produce around 500 tons of NMN by 2025, while Swisse and other brands are launching related products [7][27] - The industry is witnessing a shift towards the commercialization of NAD+ precursors, with NR and NMN leading the way in research and product availability [5][24]